Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy

Silvia Brunelli, Clara Sciorati, Giuseppe D'Antona, Anna Innocenzi, Diego Covarello, Beatriz G. Galvez, Cristiana Perrotta, Angela Monopoli, Francesca Sanvito, Roberto Bottinelli, Ennio Ongini, Giulio Cossu, Emilio Clementi

Research output: Contribution to journalArticle

136 Citations (Scopus)

Abstract

Duchenne muscular dystrophy is a relatively common disease that affects skeletal muscle, leading to progressive paralysis and death. There is currently no resolutive therapy. We have developed a treatment in which we combined the effects of nitric oxide with nonsteroidal antiinflammatory activity by using HCT 1026, a nitric oxide-releasing derivative of flurbiprofen. Here, we report the results of long-term (1-year) oral treatment with HCT 1026 of two murine models for limb girdle and Duchenne muscular dystrophies (α-sarcoglycan-null and mdx mice). In both models, HCT 1026 significantly ameliorated the morphological, biochemical, and functional phenotype in the absence of secondary effects, efficiently slowing down disease progression. HCT 1026 acted by reducing inflammation, preventing muscle damage, and preserving the number and function of satellite cells. HCT 1026 was significantly more effective than the corticosteroid prednisolone, which was analyzed in parallel. As an additional beneficial effect, HCT 1026 enhanced the therapeutic efficacy of arterially delivered donor stem cells, by increasing 4-fold their ability to migrate and reconstitute muscle fibers. The therapeutic strategy we propose is not selective for a subset of mutations; it provides ground for immediate clinical experimentation with HCT 1026 alone, which is approved for use in humans; and it sets the stage for combined therapies with donor or autologous, genetically corrected stem cells.

Original languageEnglish
Pages (from-to)264-269
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume104
Issue number1
DOIs
Publication statusPublished - Jan 2 2007

Fingerprint

Muscular Dystrophies
Cell- and Tissue-Based Therapy
Nitric Oxide
Anti-Inflammatory Agents
Stem Cells
Pathology
Duchenne Muscular Dystrophy
Therapeutics
Sarcoglycans
Limb-Girdle Muscular Dystrophies
Inbred mdx Mouse
Flurbiprofen
Muscles
Prednisolone
nitroflurbiprofen
Paralysis
Disease Progression
Adrenal Cortex Hormones
Skeletal Muscle
Inflammation

Keywords

  • α-sarcoglycan-null mice
  • HCT 1026
  • mdx mice
  • Satellite cells
  • Skeletal muscle

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy. / Brunelli, Silvia; Sciorati, Clara; D'Antona, Giuseppe; Innocenzi, Anna; Covarello, Diego; Galvez, Beatriz G.; Perrotta, Cristiana; Monopoli, Angela; Sanvito, Francesca; Bottinelli, Roberto; Ongini, Ennio; Cossu, Giulio; Clementi, Emilio.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 104, No. 1, 02.01.2007, p. 264-269.

Research output: Contribution to journalArticle

Brunelli, Silvia ; Sciorati, Clara ; D'Antona, Giuseppe ; Innocenzi, Anna ; Covarello, Diego ; Galvez, Beatriz G. ; Perrotta, Cristiana ; Monopoli, Angela ; Sanvito, Francesca ; Bottinelli, Roberto ; Ongini, Ennio ; Cossu, Giulio ; Clementi, Emilio. / Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy. In: Proceedings of the National Academy of Sciences of the United States of America. 2007 ; Vol. 104, No. 1. pp. 264-269.
@article{9b976716507e42928340005d7283c684,
title = "Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy",
abstract = "Duchenne muscular dystrophy is a relatively common disease that affects skeletal muscle, leading to progressive paralysis and death. There is currently no resolutive therapy. We have developed a treatment in which we combined the effects of nitric oxide with nonsteroidal antiinflammatory activity by using HCT 1026, a nitric oxide-releasing derivative of flurbiprofen. Here, we report the results of long-term (1-year) oral treatment with HCT 1026 of two murine models for limb girdle and Duchenne muscular dystrophies (α-sarcoglycan-null and mdx mice). In both models, HCT 1026 significantly ameliorated the morphological, biochemical, and functional phenotype in the absence of secondary effects, efficiently slowing down disease progression. HCT 1026 acted by reducing inflammation, preventing muscle damage, and preserving the number and function of satellite cells. HCT 1026 was significantly more effective than the corticosteroid prednisolone, which was analyzed in parallel. As an additional beneficial effect, HCT 1026 enhanced the therapeutic efficacy of arterially delivered donor stem cells, by increasing 4-fold their ability to migrate and reconstitute muscle fibers. The therapeutic strategy we propose is not selective for a subset of mutations; it provides ground for immediate clinical experimentation with HCT 1026 alone, which is approved for use in humans; and it sets the stage for combined therapies with donor or autologous, genetically corrected stem cells.",
keywords = "α-sarcoglycan-null mice, HCT 1026, mdx mice, Satellite cells, Skeletal muscle",
author = "Silvia Brunelli and Clara Sciorati and Giuseppe D'Antona and Anna Innocenzi and Diego Covarello and Galvez, {Beatriz G.} and Cristiana Perrotta and Angela Monopoli and Francesca Sanvito and Roberto Bottinelli and Ennio Ongini and Giulio Cossu and Emilio Clementi",
year = "2007",
month = "1",
day = "2",
doi = "10.1073/pnas.0608277104",
language = "English",
volume = "104",
pages = "264--269",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "1",

}

TY - JOUR

T1 - Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy

AU - Brunelli, Silvia

AU - Sciorati, Clara

AU - D'Antona, Giuseppe

AU - Innocenzi, Anna

AU - Covarello, Diego

AU - Galvez, Beatriz G.

AU - Perrotta, Cristiana

AU - Monopoli, Angela

AU - Sanvito, Francesca

AU - Bottinelli, Roberto

AU - Ongini, Ennio

AU - Cossu, Giulio

AU - Clementi, Emilio

PY - 2007/1/2

Y1 - 2007/1/2

N2 - Duchenne muscular dystrophy is a relatively common disease that affects skeletal muscle, leading to progressive paralysis and death. There is currently no resolutive therapy. We have developed a treatment in which we combined the effects of nitric oxide with nonsteroidal antiinflammatory activity by using HCT 1026, a nitric oxide-releasing derivative of flurbiprofen. Here, we report the results of long-term (1-year) oral treatment with HCT 1026 of two murine models for limb girdle and Duchenne muscular dystrophies (α-sarcoglycan-null and mdx mice). In both models, HCT 1026 significantly ameliorated the morphological, biochemical, and functional phenotype in the absence of secondary effects, efficiently slowing down disease progression. HCT 1026 acted by reducing inflammation, preventing muscle damage, and preserving the number and function of satellite cells. HCT 1026 was significantly more effective than the corticosteroid prednisolone, which was analyzed in parallel. As an additional beneficial effect, HCT 1026 enhanced the therapeutic efficacy of arterially delivered donor stem cells, by increasing 4-fold their ability to migrate and reconstitute muscle fibers. The therapeutic strategy we propose is not selective for a subset of mutations; it provides ground for immediate clinical experimentation with HCT 1026 alone, which is approved for use in humans; and it sets the stage for combined therapies with donor or autologous, genetically corrected stem cells.

AB - Duchenne muscular dystrophy is a relatively common disease that affects skeletal muscle, leading to progressive paralysis and death. There is currently no resolutive therapy. We have developed a treatment in which we combined the effects of nitric oxide with nonsteroidal antiinflammatory activity by using HCT 1026, a nitric oxide-releasing derivative of flurbiprofen. Here, we report the results of long-term (1-year) oral treatment with HCT 1026 of two murine models for limb girdle and Duchenne muscular dystrophies (α-sarcoglycan-null and mdx mice). In both models, HCT 1026 significantly ameliorated the morphological, biochemical, and functional phenotype in the absence of secondary effects, efficiently slowing down disease progression. HCT 1026 acted by reducing inflammation, preventing muscle damage, and preserving the number and function of satellite cells. HCT 1026 was significantly more effective than the corticosteroid prednisolone, which was analyzed in parallel. As an additional beneficial effect, HCT 1026 enhanced the therapeutic efficacy of arterially delivered donor stem cells, by increasing 4-fold their ability to migrate and reconstitute muscle fibers. The therapeutic strategy we propose is not selective for a subset of mutations; it provides ground for immediate clinical experimentation with HCT 1026 alone, which is approved for use in humans; and it sets the stage for combined therapies with donor or autologous, genetically corrected stem cells.

KW - α-sarcoglycan-null mice

KW - HCT 1026

KW - mdx mice

KW - Satellite cells

KW - Skeletal muscle

UR - http://www.scopus.com/inward/record.url?scp=33846043968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846043968&partnerID=8YFLogxK

U2 - 10.1073/pnas.0608277104

DO - 10.1073/pnas.0608277104

M3 - Article

C2 - 17182743

AN - SCOPUS:33846043968

VL - 104

SP - 264

EP - 269

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 1

ER -